JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Found 321 products of "JAK/STAT signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BP-5-087
CAS:<p>BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.</p>Formula:C36H30F8N2O6SColor and Shape:SolidMolecular weight:770.69Galiellalactone
CAS:<p>inhibits IL-6-mediated JAK/STAT signal transduction</p>Formula:C11H14O3Purity:98%Color and Shape:SolidMolecular weight:194.23CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34YM-341619
CAS:<p>YM-341619 (AS1617612), potent STAT6 inhibitor; IC50: 0.70 nM; hinders IL-4-induced Th2 in mice; may aid allergic disease research.</p>Formula:C22H21F3N6O2Color and Shape:SolidMolecular weight:458.44TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formula:C22H25F2N5O2Color and Shape:SolidMolecular weight:429.46Stafia-1-dipivaloyloxymethyl ester
CAS:<p>Stafia-1 suppresses pSTAT5a in a dose-dependent manner (0-200 μM) without affecting pSTAT5b.</p>Formula:C37H48FO13PColor and Shape:SolidMolecular weight:750.74MM-206
CAS:<p>MM-206, a cell-permeable, non-cytotoxic naphthalene sulfonamide compound, it effectively inhibits STAT3 DNA-binding activity.</p>Formula:C22H12F5NO3S2Color and Shape:SolidMolecular weight:497.46MC0704
<p>MC0704: STAT3 inhibitor, IC50=2.13μM, promotes apoptosis & cell arrest, anti-breast cancer, for mTNBC research.</p>Formula:C29H21BrN4O2Color and Shape:SolidMolecular weight:537.41STAT3-IN-15
<p>STAT3-IN-15: Potent, oral STAT3 inhibitor for IPF, blocks STAT3 phosphorylation, cell migration, and EMT.</p>Formula:C20H17F3N2O3SColor and Shape:SolidMolecular weight:422.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formula:C28H28ClN5O4SColor and Shape:SolidMolecular weight:566.07HJC0149
CAS:<p>HJC0149 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.</p>Formula:C15H10ClNO4SColor and Shape:SolidMolecular weight:335.76TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44LLL12
CAS:<p>LLL12 inhibits STAT3 phosphorylation, boosting Cisplatin and Paclitaxel effects against ovarian cancer cell activities.</p>Formula:C14H9NO5SColor and Shape:SolidMolecular weight:303.29JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formula:C20H18FN5O3SPurity:99.53%Color and Shape:SolidMolecular weight:427.45JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Formula:C26H30ClN7O2Color and Shape:SolidMolecular weight:508.02JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formula:C25H28N8OPurity:97.89%Color and Shape:SolidMolecular weight:456.54JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Formula:C19H26N8SPurity:98%Color and Shape:SolidMolecular weight:398.53JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Formula:C20H18ClN7OPurity:98%Color and Shape:SolidMolecular weight:407.86AZD-1897
CAS:<p>AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.</p>Formula:C18H23N3O3SPurity:99.49%Color and Shape:SolidMolecular weight:361.46M-110
CAS:<p>M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).</p>Formula:C22H28ClN5O3Purity:99.55%Color and Shape:SolidMolecular weight:445.94JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formula:C25H32N8O2Purity:99.64% - 99.87%Color and Shape:SolidMolecular weight:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formula:C18H15FN4O3Purity:98.61% - 99.81%Color and Shape:SolidMolecular weight:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25PIM-1 Inhibitor 2
CAS:<p>PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.</p>Formula:C17H11ClN4OPurity:98.81%Color and Shape:SolidMolecular weight:322.75JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formula:C22H23FN4O3SPurity:98.4%Color and Shape:SolidMolecular weight:442.51STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formula:C15H15ClN4O2Purity:99.01%Color and Shape:SolidMolecular weight:318.76Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formula:C22H26N8Purity:99.82%Color and Shape:SolidMolecular weight:402.50JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Formula:C21H21N5O2Purity:99.59%Color and Shape:SolidMolecular weight:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formula:C29H32Cl2N2O5SPurity:99.51% - 99.83%Color and Shape:SoildMolecular weight:591.55NT219
CAS:<p>NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.</p>Formula:C16H14BrNO5SPurity:98.06% - 99.72%Color and Shape:SolidMolecular weight:412.26Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39PM-43I
CAS:<p>PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.</p>Formula:C38H50F2N3O10PColor and Shape:SolidMolecular weight:777.79JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formula:C27H25F3N4O4Purity:99.39% - ≥98%Color and Shape:SolidMolecular weight:526.51STAT3-IN-14
CAS:<p>STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .</p>Formula:C14H10O5Color and Shape:SolidMolecular weight:258.23Pim-1 kinase inhibitor 5
CAS:<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Formula:C22H13Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:406.26JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44PIM1-IN-4
CAS:<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Formula:C27H25BrCl2CuN6OPurity:98%Color and Shape:SolidMolecular weight:663.88JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44GNE-955
CAS:<p>GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).</p>Formula:C22H24N8OPurity:98%Color and Shape:SolidMolecular weight:416.48PIM1-IN-1
CAS:<p>PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.</p>Formula:C25H30N8O2Purity:98%Color and Shape:SolidMolecular weight:474.56Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Formula:C42H70O12Purity:98.46% - 99.13%Color and Shape:SolidMolecular weight:767Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66JAK2-IN-4
CAS:<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Formula:C23H27N5O4SPurity:98%Color and Shape:SolidMolecular weight:469.56JAK-IN-5
CAS:<p>JAK-IN-5 is a JAK inhibitor.</p>Formula:C27H31FN6OPurity:98.1% - 99.37%Color and Shape:SolidMolecular weight:474.57STAT3 degrader-2
CAS:<p>STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and various</p>Formula:C59H62N9O13PPurity:98%Color and Shape:SolidMolecular weight:1136.15TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74JAK-IN-31
CAS:<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Formula:C21H19N7O2S2Purity:98%Color and Shape:SolidMolecular weight:465.55QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formula:C26H27N7O3Purity:98%Color and Shape:SolidMolecular weight:485.54Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColor and Shape:SolidMolecular weight:505.01FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formula:C24H28N4O5Purity:98%Color and Shape:SolidMolecular weight:452.5PIM-IN-2
CAS:<p>PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .</p>Formula:C19H22N4O2Purity:98%Color and Shape:SolidMolecular weight:338.4STAT6-IN-1
CAS:<p>STAT6-IN-1: STAT6 inhibitor, IC50=0.028 µM, targets SH2 domain, for allergy and cancer research.</p>Formula:C33H37IN3O7PColor and Shape:SolidMolecular weight:745.54FD1024
CAS:<p>FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.</p>Formula:C21H20F2N4O2SPurity:98%Color and Shape:SolidMolecular weight:430.47HS94
CAS:<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Formula:C15H15N5O2SPurity:95.04%Color and Shape:SolidMolecular weight:329.38JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formula:C20H18F2N6O5SColor and Shape:SolidMolecular weight:492.46Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37STAT3-IN-7
CAS:<p>STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.</p>Formula:C30H26F5N5O4SColor and Shape:SolidMolecular weight:647.62JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Color and Shape:SolidJAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37SI-109
CAS:<p>SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.</p>Formula:C40H44F2N7O9PPurity:98%Color and Shape:SolidMolecular weight:835.79(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formula:C20H27ClN6OColor and Shape:SolidMolecular weight:402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formula:C20H15ClF3N3OSColor and Shape:SolidMolecular weight:437.87JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463Prohibitin ligand 1
<p>Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.</p>Formula:C20H22N2OColor and Shape:SolidMolecular weight:306.4GDC-0339
CAS:<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Formula:C20H22F3N7OSColor and Shape:SolidMolecular weight:465.5CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65Tyk2-IN-14
CAS:<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47Pim-1 kinase inhibitor 6
CAS:<p>Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].</p>Formula:C21H10BrCl2N3Color and Shape:SolidMolecular weight:455.13Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50JDTic
CAS:<p>JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.</p>Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63(3R,4S)-Tofacitinib
CAS:<p>(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.</p>Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK2-IN-9
CAS:<p>Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.</p>Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.51JAK-IN-27
CAS:<p>JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM</p>Formula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42JAK1-IN-10
CAS:<p>JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].</p>Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34JAK-IN-34
CAS:<p>JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,</p>Formula:C27H26N6OPurity:98%Color and Shape:SolidMolecular weight:450.53STAT3-IN-18
CAS:<p>STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and</p>Formula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38JAK1-IN-11
CAS:<p>JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.</p>Formula:C26H36N6O4SPurity:98%Color and Shape:SolidMolecular weight:528.67DPP
CAS:<p>DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating</p>Formula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7
